Methods
Asthmatic patients treated with omalizumab between February 2013 and June 2014 were evaluated retrospectively. The conditions under Omalizumab was prescribed and ACT improvements were evaluated.
Results
A total of 19 patients (14 females and 5 males) were prescribed omalizumab. Prescribing criteria were: one or more ED visits in the last year (100%); high dose inhaled corticosteroid and long-acting beta2agonist use (94.7%); systemic corticosteroid use more than 3 times the last year (89.5%); FEV<80% (78.9%); daily short-acting beta2agonist use (68.4%); fast pulmonary function deterioration after systemic corticosteroid withdrawal (52.6%); death threatening asthma exacerbation episode (42%). Seven of these patients had a 16 week course of omalizumab with a significant improvement in ACT total score in six of them (86%).
Conclusions
In our casuistic, the main criteria omalizumab was prescribed for severe asthma was ED visits. Omalizumab promoted a significant improvement in most patients' ACT total score.
